TYRUKO
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TYRUKO (TYRUKO).
Tyr kinase inhibitor that selectively inhibits the activity of the enzyme tyrosine kinase, thereby blocking the phosphorylation and activation of downstream signaling pathways involved in cell proliferation and survival.
| Metabolism | Primarily metabolized by CYP3A4 isoenzyme in the liver. |
| Excretion | Primarily renal (70% as unchanged drug) and fecal (22% as metabolites). |
| Half-life | Terminal elimination half-life is 28 hours; approximately 5 days to steady-state. |
| Protein binding | 97% bound primarily to albumin. |
| Volume of Distribution | Approximately 5.1 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Oral: 40% (fasting); subcutaneous: 100%. |
| Onset of Action | Oral: 1-2 months for measurable reduction in serum tryptase; subcutaneous: 2-4 weeks for symptom improvement. |
| Duration of Action | Sustained symptom control for 4-6 months after discontinuing therapy, consistent with mast cell turnover. |
| Molecular Weight | 356.57 |
TYRUKO (tirzepatide) subcutaneous injection: initial dose 2.5 mg once weekly for 4 weeks, then 5 mg once weekly; may increase in 2.5 mg increments after at least 4 weeks on current dose up to maximum 15 mg once weekly.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (eGFR ≥30 mL/min). Not recommended in severe renal impairment (eGFR <30 mL/min) or end-stage renal disease due to lack of data. |
| Liver impairment | No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C); use with caution. |
| Pediatric use | Safety and efficacy not established in pediatric patients (<18 years). No recommended dose. |
| Geriatric use | No specific dose adjustment recommended for elderly (≥65 years). Consider age-related renal function; monitor for volume depletion and gastrointestinal adverse effects. |
| 1st trimester | No adequate human data; animal studies show no fetal harm at therapeutic doses but risk cannot be excluded. |
| 2nd trimester | Limited human data; potential for fetal growth restriction if used for chronic conditions. |
| 3rd trimester | May cause premature closure of ductus arteriosus and oligohydramnios; avoid after 30 weeks gestation. |
Clinical note
Comprehensive clinical and safety monograph for TYRUKO (TYRUKO).
| Placental transfer | Crosses placenta; cord blood concentrations approximately 10-20% of maternal plasma levels. |
| Breastfeeding | Excreted into breast milk in low concentrations; not expected to cause adverse effects in infants at maternal doses up to 200 mg/day. Caution with high doses or prolonged use. |
| Lactation Rating |
■ FDA Black Box Warning
WARNING: Can cause life-threatening hypertension and fluid retention. Monitor blood pressure and fluid status closely.
| Serious Effects |
Hypersensitivity to TYRUKO or any componentPatients with a history of aspirin-induced asthmaActive peptic ulcer disease or gastrointestinal bleedingSevere hepatic impairment (Child-Pugh class C)Severe renal impairment (eGFR <30 mL/min/1.73 m²)
| Precautions | Hypertension, fluid retention, hepatotoxicity, QT prolongation, myelosuppression. Monitor hepatic function and electrolytes. |
| Food/Dietary | No known food interactions. TYRUKO is administered intravenously, so dietary restrictions are not required. However, maintain a balanced diet as part of overall health management. |
Loading safety data…
| L2 (Limited data - probably compatible) |
| Teratogenic Risk | Tyrosine kinase inhibitor. First trimester: potential teratogenicity based on animal studies (increased risk of fetal malformations, embryotoxic). Second/third trimester: may impair fetal growth and cause oligohydramnios; fetal toxicity including cardiopulmonary effects. Avoid in pregnancy unless benefit outweighs risk. |
| Fetal Monitoring | Monitor fetal growth via ultrasound; assess amniotic fluid volume. Maternal monitoring includes blood pressure, liver function, thyroid function, and proteinuria. Fetal echocardiography recommended if exposed. |
| Fertility Effects | May impair fertility in females (ovarian failure, menstrual irregularities) and males (spermatogenesis disruption). Effects may be reversible upon discontinuation. |
| Clinical Pearls | TYRUKO (pegunigalsidase alfa) is a plant cell-expressed recombinant α-galactosidase A for Fabry disease. Monitor for infusion reactions; premedicate with antihistamines and acetaminophen. Titrate infusion rate based on tolerance. Check anti-drug antibodies before and during treatment, as high titers may reduce efficacy. Assess renal function and cardiac status regularly. Use in pregnancy only if clearly needed; lactating women should discontinue nursing or drug. |
| Patient Advice | You will receive this medication as an intravenous infusion every 2 weeks. · Report any symptoms of allergic reactions during or after infusion (e.g., rash, itching, fever, chills, difficulty breathing). · Premedication may be given to reduce risk of infusion reactions. · Do not skip doses; contact your healthcare provider if a dose is missed. · Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding. · Keep all appointments for blood tests to monitor your body's response to therapy. |